drugset / Trial / NCT03251716

Berberine Treat Metabolic Syndrome in Schizophrenia

NCT03251716

Completed 36 enrolled Tianjin Anding Hospital
NaSingle-groupOpen-labelTreatment

Summary

In early clinical study investigators confirmed that berberine could prevent glucose and lipid metabolism disorder in schizophrenia, so investigators intend to verify the effect and safety of berberine in treatment for metabolic syndrome in schizophrenia.

Timeline

Start
2015-01-01
Primary completion
2017-10-30
Completion
2017-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Berberine Traditional medicine (herbal / TCM) 300 mg